Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 44.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000D81 | G. Fenelon [France] ; S. Gimenez-Roldan [Espagne] ; J. L. Montastruc [France] ; F. Bermejo [Espagne] ; F. Durif [France] ; I. Bourdeix [France] ; J.-J. Pere [Espagne] ; L. Galiano [Suisse] ; J. Schadrack | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study |
| 000E32 | J. L. Montastruc [France] ; O. Rascol [France] | Propriétés pharmacodynamiques des agonistes dopaminergiques ? Quelle transférabilité en pratique clinique dans le traitement de la maladie de Parkinson ? |
| 000F34 | A. Angles [France] ; H. Bagheri [France] ; S. Saivin [France] ; J. L. Montastruc [France] | Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease |
| 001064 | O. Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France] | Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease |
| 001230 | U. Sabatini [France] ; K. Boulanouar [France, Italie] ; N. Fabre [France] ; F. Martin [France] ; C. Carel [France] ; C. Colonnese [Italie] ; L. Bozzao [Italie] ; I. Berry [France] ; J. L. Montastruc [France] ; F. Chollet [France] ; O. Rascol [France] | Cortical motor reorganization in akinetic patients with Parkinson's disease: A functional MRI study |
| 001290 | J. L. Montastruc [France] ; O. Rascol [France] ; J.-M. Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 001430 | N. Fabre [France] ; C. Brefel [France] ; U. Sabatini [Italie] ; P. Celsis [France] ; J. L. Montastruc [France] ; F. Chollet [France] ; O. Rascol [France] | Normal frontal perfusion in patients with frozen gait |
| 001448 | J. L. Montastruc [France] ; M. Pelat [France] ; P. Verwaerde [France] ; C. Brefel-Courbon [France] ; M. A. Tran [France] ; O. Blin [France] ; O. Rascol [France] ; J. M. Senard [France] | Fluoxetine in orthostatic hypotension of Parkinson's disease : A clinical and experimental pilot study |
| 001454 | C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France] | Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients |
| 001456 | U. K. Rinne [Finlande] ; F. Bracco [Italie] ; C. Chouza [Uruguay] ; E. Dupont [Danemark] ; O. Gershanik [Argentine] ; J. F. Marti Masso [Espagne] ; J. L. Montastruc [France] ; C. D. Marsden [Royaume-Uni] | Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial |
| 001461 | O. Rascol [France] ; U. Sabatini [France, Italie] ; C. Brefel [France] ; N. Fabre [France] ; S. Rai [France] ; J. M. Senard [France] ; P. Celsis [France] ; G. Viallard [France] ; J. L. Montastruc [France] ; F. Chollet [France] | Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia |
| 001546 | O. Rascol [France] ; U. Sabatini [Italie] ; N. Fabre [France] ; C. Brefel [France] ; I. Loubinoux [France] ; P. Celsis [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; F. Chollet [France] | The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients |
| 001557 | J. M. Senard [France] ; S. Rai [France] ; M. Lapeyre-Mestre [France] ; C. Brefel [France] ; O. Rascol [France] ; A. Rascol [France] ; J. L. Montastruc [France] | Prevalence of orthostatic hypotension in Parkinson's disease |
| 001576 | J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France] | Glutamate antagonists and Parkinson's disease : A review of clinical data |
| 001590 | U. K. Rinne [Finlande] ; F. Bracco [Italie] ; C. Chouza [Uruguay] ; E. Dupont [Danemark] ; O. Gershanik [Argentine] ; J. F. Marti Masso [Espagne] ; J. L. Montastruc [France] ; C. D. Marsden [Royaume-Uni] ; A. Dubini [Italie] ; N. Orlando [Italie] ; R. Grimaldi [Italie] | Cabergoline in the treatment of early Parkinson's disease : Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa |
| 001636 | O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. Fuell | Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease |
| 001703 | P. Allain [France] ; A. Le Bouil [France] ; E. Cordillet [France] ; L. Le Quay [France] ; H. Bagheri [France] ; J. L. Montastruc | Sulfate and cysteine levels in the plasma of patients with Parkinson's disease |
| 001791 | O. Rascol [France] ; U. Sabatini [France] ; F. Chollet [France] ; N. Fabre [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; P. Calsis [France] ; J. P. Marc-Vergnes [France] ; A. Rascol [France] | Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa |
| 001795 | O. Blin [France] ; C. Desnuelle ; O. Rascol ; M. Borg ; H. Peyro Saint Paul ; J. P. Azulay [France] ; F. Bille [France] ; D. Figarella [France] ; F. Coulom [France] ; J. F. Pellissier [France] ; J. L. Montastruc ; M. Chatel ; G. Serratrice [France] | Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy |
| 001798 | H. Bagheri [France] ; M. Berlan ; J. M. Senard ; O. Rascol ; J. L. Montastruc | Lacrimation in Parkinson's disease |
| 001804 | J. L. Montastruc [France] ; M. E. Llau ; O. Rascol ; J. M. Senard | Drug-induced parkinsonism : a review |
| 001816 | J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France] ; A. Rascol | A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease : a five year follow up |
| 001874 | J. M. Senard [France] ; O. Rascol [France] ; A. Rascol ; J. L. Montastruc [France] | Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension |
| 001885 | J. M. Senard [France] ; O. Rascol [France] ; G. Durrieu [France] ; M. A. Tran [France] ; M. Berlan [France] ; A. Rascol ; J. L. Montastruc | Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy |
| 001893 | J. L. Montastruc [France] ; O. Rascol ; J. M. Senard | Current status of dopamine agonists in Parkinson's disease management |
| 001900 | N. Fabre [France] ; J. L. Montastruc ; O. Rascol | Alopecia : an adverse effect of bromocriptine |
| 001999 | U. Sabatini [France] ; O. Rascol ; P. Celsis ; G. Houin ; A. Rascol ; J. P. Marc-Vergnes ; J. L. Montastruc | Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms |
| 001A00 | O. Rascol [France] ; U. Sabatini ; SIMONETTA-MOREAU ; J. L. Montastruc ; A. Rascol ; M. Clanet | Square wave jerks in Parkinsonian syndromes |
| 001A04 | J. L. Montastruc [France] | Recent advances in the clinical pharmacology of Parkinson's disease |
| 001A17 | A. Agniel [France] ; P. Celsis ; G. Viallard ; J. L. Montastruc ; J. F. Demonet ; J. P. Marc-Vergnes ; A. Rascol | Cognition and cerebral blood flow in lateralised Parkinsonism : lack of functional lateral asymmetries |
| 001A43 | J. L. Montastruc ; O. Rascol ; A. Rascol | Comparison de la bromocriptine et de la levodopa dans le traitement de première intention de la maladie de Parkinson : résultats à 3 ans d'une étude prospective randomisée |
| 001A65 | J. L. Montastruc | A propos de l'étude DATATOP : déprényl® (sélégiline) dans le traitement de la maladie de Parkinson |
| 001B01 | O. Rascol ; M. Clanet ; J. L. Montastruc ; M. Simonetta ; M. J. Soulier-Esteve ; B. Doyon ; A. Rascol | Abnormal ocular movements in Parkinson's disease: evidence for involvement of dopaminergic systems |
| 001B17 | J.-P. Marc-Vergnes ; P. Celsis ; J. L. Montastruc ; J. F. Demonet ; A. Agniel ; O. Rascol ; G. Viallard ; B. Doyon ; A. Rascol | Hémodynamique cérébrale et pharmacologie clinique dans la maladie de Parkinson |
| 001B18 | P. Celsis ; O. Rascol ; J. F. Demonet ; A. Agniel ; J. L. Montastruc ; J. P. Marc-Vergnes ; A. Rascol | Effet de la bromocriptine sur le débit sanguin cérébral dans la maladies de Parkinson |
| 001B20 | J. L. Montastruc ; O. Rascol ; A. Rascol | Bromocriptine versus levodopa dans le traitement de première intention de la maladie de Parkinson. Premiers résultats à deux ans |
| 001B21 | O. Rascol ; J. L. Montastruc ; J. M. Senard ; J. F. Demonet ; M. Simonetta ; A. Rascol | Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial |
| 001B46 | M. Simonetta ; L. Schmitt ; J. L. Montastruc ; A. Rascol | Effets neuropsychiques secondaires de la bromocriptine dans la maladie de Parkinson |
| 001B58 | J. L. Montastruc ; P. Celsis ; A. Agniel ; J. F. Demonet ; B. Doyon ; M. Puel ; J. P. Marc-Vergnes ; A. Rascol | Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease: lack of correlation with clinical or neuropsychological improvements |
| 001B63 | J. L. Montastruc ; O. Rascol ; J. Belin ; M. Ane ; A. Rascol | Does papaverine interact with levodopa in Parkinson's disease? |
| 001B76 | J. F. Demonet ; M. Rostin ; J. M. Dueymes ; A. Ioualalen ; J. L. Montastruc ; A. Rascol | Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine |
| 001B78 | A. Rascol ; J. L. Montastruc ; O. Rascol ; J. M. Senard | Mesulergine (CU 32-085) in the treatment of Parkinson's disease |
| 001B85 | T. Venisse ; J. L. Montastruc ; A. Rascol | Pharmacologie clinique et traitement de la maladie de Parkinson |
| 001B97 | J. L. Montastruc ; A. Rascol | Traitement de la maladie de Parkinson par doses élevées de bromocriptine: interaction possible avec la josamycine |
| This area was generated with Dilib version V0.6.29. |  |